Why GHRP-2 and GHRP-6 May Stay Banned: The FDA's Safety Concerns

Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Explore the FDA's safety concerns regarding GHRP-2 and GHRP-6. Learn why these popular growth hormone-releasing peptides are banned from compounding.

Why GHRP-2 and GHRP-6 May Stay Banned: The FDA's Safety Concerns

The world of peptide therapy is dynamic, with new research and regulatory changes constantly emerging. Among the most discussed topics is the GHRP-2 GHRP-6 FDA ban, a decision rooted in significant safety concerns. These Growth Hormone-Releasing Peptides have been popular for their potential to stimulate the body's own growth hormone production, but the U.S. Food and Drug Administration (FDA) has placed them in a category of substances that may present significant safety risks when compounded. This article delves into the specific reasons behind the FDA's stance on GHRP-2 and GHRP-6, exploring the potential risks that led to their current regulatory status.

For those navigating the complex landscape of peptide treatments, understanding these regulations is crucial. You can find more foundational information in our Peptide Therapy Guide.

Understanding GHRP-2 and GHRP-6

GHRP-2 (Growth Hormone-Releasing Peptide 2) and GHRP-6 (Growth Hormone-Releasing Peptide 6) are synthetic molecules known as secretagogues. Their primary function is to stimulate the pituitary gland to release growth hormone (GH). They achieve this by mimicking ghrelin, a natural hormone, and binding to its receptors in the brain.

  • GHRP-6 was the first of its kind developed and is known for a potent GH release, but also for significantly increasing appetite and gastric motility.
  • GHRP-2 is a second-generation GHRP, offering a similarly potent GH release but with less of an impact on appetite, though it may have a more pronounced effect on cortisol and prolactin levels.

    • These peptides have been studied for their potential in treating GH deficiencies, cachexia, and other conditions, but their use outside of controlled research has raised flags for regulators. A deeper dive into various peptides can be found in our compounds library.

    The FDA's Position: A Matter of Safety

    In September 2023, the FDA placed both GHRP-2 and GHRP-6 on its list of bulk drug substances that may present "significant safety risks" when used in compounding FDA.gov. This decision effectively bans their use by compounding pharmacies for injectable and, in the case of GHRP-2, nasal administration. The FDA's concerns are not singular but are based on a collection of potential issues identified during their review.

    The core of the issue lies in the lack of comprehensive, long-term safety data for widespread public use and specific risks associated with the molecular structure and manufacturing of these peptides.

    The specialists at TeleGenix can help you understand the current landscape of peptide therapies and guide you toward safe and effective, federally-approved treatments.

    Detailed Safety Concerns for GHRP-2

    The FDA has outlined several key safety risks associated with compounded GHRP-2. The GHRP-2 GHRP-6 FDA ban is heavily influenced by these specific points.

  • Immunogenicity Risk: The FDA notes that compounded drugs containing GHRP-2 may pose a risk of immunogenicity, which is the ability of a substance to trigger an immune response. This can be due to the potential for the peptide to form aggregates (clumps) and the presence of peptide-related impurities from the manufacturing process. An unwanted immune response could neutralize the peptide's effects or cause other health complications.
  • Unnatural Amino Acid: GHRP-2's structure contains an unnatural amino acid (D-Alanine). The FDA highlights that this adds to the complexity of characterizing the peptide and its impurities, making it harder to ensure the safety and consistency of the final compounded product.
  • Serious Adverse Event Reports: The agency stated it is aware of reports of serious adverse events in patients who received GHRP-2. While causality has not been definitively established, the reported events are alarming and include:

    • Increased insulin requirement to maintain blood glucose levels.

    Death of critically ill study subjects.

    Infection and pancreatitis.

    These reports, even without proven causality, contribute to a high-risk profile for the substance when used outside of rigorous clinical trials PMID: 12030918.

    Detailed Safety Concerns for GHRP-6

    Similarly, GHRP-6 has its own set of safety concerns that contributed to its inclusion on the FDA's list.

  • Immunogenicity Risk: Like GHRP-2, GHRP-6 carries a risk of immunogenicity due to potential aggregation and impurities. This risk is a common theme for many complex peptides sourced for compounding.
  • Limited Safety Data, Concerning Signals: The FDA acknowledges that there is limited safety-related information on GHRP-6. However, the available data reveal concerning signals. Studies have shown that GHRP-6 can affect cortisol levels and, more significantly, increase blood glucose due to decreases in insulin sensitivity PMID: 9285939. This potential to disrupt metabolic function is a major red flag for regulators.
  • Long-Term Effects Unknown: The long-term safety of GHRP-6, particularly regarding its impact on metabolic health and cancer risk, has not been sufficiently evaluated. The absence of long-term studies makes it difficult to justify its widespread use in a wellness or anti-aging context PMID: 29082119.

    • GHRP-2 vs. GHRP-6: A Comparison of Risks

    To clarify the distinctions, the following table compares the key characteristics and FDA-noted safety concerns for both peptides.

    | Feature | GHRP-2 | GHRP-6 |

    | :--- | :--- | :--- |

    | Primary Function | Potent GH Secretagogue | Potent GH Secretagogue |

    | Appetite Stimulation | Low to moderate | High |

    | Effect on Cortisol/PRL | Moderate increase | Slight increase |

    | Key FDA Safety Concern | Immunogenicity, unnatural amino acid, serious adverse event reports | Immunogenicity, potential effect on cortisol and blood glucose |

    | Structural Note | Contains an unnatural D-amino acid | Composed of natural L-amino acids |

    | FDA Category | Category 2 (Banned for Compounding) | Category 2 (Banned for Compounding) |

    This table illustrates that while both peptides are effective GH secretagogues, they carry distinct risk profiles that the FDA has deemed significant. For more comparisons of different compounds, visit our comparison page.

    The Future of Peptide Regulation

    The FDA's actions on GHRP-2 and GHRP-6 are part of a broader effort to regulate the compounding of peptides and ensure patient safety. While some peptides have been moved from the high-risk Category 2 to the less restrictive Category 1, GHRP-2 and GHRP-6 remain under scrutiny. The path forward for these substances would require substantial new evidence demonstrating their safety and a clear, unmet medical need that outweighs their risks.

    For those seeking hormone-related treatments, it's important to consider all options. The specialists at TeleGenix can provide information on FDA-approved therapies, including options available in our Testosterone Library.

    Conclusion

    The GHRP-2 GHRP-6 FDA ban is a direct result of identified safety risks, including immunogenicity, potential metabolic disruption, and reports of serious adverse events. While these peptides show promise in their ability to stimulate growth hormone, the lack of comprehensive safety data and the presence of concerning signals have led the FDA to restrict their use in compounding. Patients and providers must respect these regulatory decisions and prioritize treatments that have been proven to be both safe and effective through rigorous scientific and clinical evaluation.

    References

  • U.S. Food and Drug Administration. (2023). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA.gov
  • Van den Berghe, G., et al. (2002). The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clinical Endocrinology, 56(5), 655-669. PMID: 12030918
  • Arvat, E., et al. (1997). Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides, 18(6), 885-891. PMID: 9285939
  • Sigalos, J. T., & Pastuszak, A. W. (2017). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual medicine reviews, 6(1), 45-53. PMID: 29082119
  • Berlanga-Acosta, J., et al. (2017). Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clinical Medicine Insights. Cardiology, 11, 1179546817694558. PMID: 28405193

    • Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any treatment.*

    ---

    Related Articles

  • 10 Peptide Therapy Misconceptions: Setting the Record Straight
  • 2023 Year in Review: The Year the FDA Banned 19 Peptides
  • 2024 Year in Review: FDA Peptide Actions and Legal Battles
  • 2025 Year in Review: FDA Peptide Regulation Highlights